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Echocardiography is a reliable and reproducible method to assess non-invasively cardiac function in 
clinical and experimental research. Significant progress in the development of echocardiographic 
equipment and transducers has led to the successful translation of this methodology from humans 
to rodents, allowing for the scoring of disease severity and progression, testing of new drugs, and 
monitoring cardiac function in genetically modified or pharmacologically treated animals. However, 
as yet, there is no standardization in the procedure to acquire echocardiographic measurements in 
small animals. This position paper focuses on the appropriate acquisition and analysis of 
echocardiographic parameters in adult mice and rats, and provides reference values, representative 
images and videos for the accurate and reproducible quantification of left ventricular function in 












Monitoring the function of the left ventricle (LV) is a key element in experimental studies aimed at 
understanding the pathophysiology of cardiac diseases and in exploring the beneficial effect of 
innovative therapies. Echocardiography is often the technique of choice to evaluate cardiac function 
in rodents, with the advantage that it is non-invasive, safe, reproducible, widely available, and 
inexpensive. The efficacy of new therapeutics in small animal models is key for their further 
application in larger animal models and humans 1, 2. However, only a small percentage of the 
therapeutics showing efficacy in small animals actually progresses to clinical use 3, 4. One of the 
possible reasons for this lack of translatability is the nonexistence of standards and minimal 
requisites to ensure reliable and accurate evaluation of cardiac function in rodents. A detailed 
description and standardization of the methods used for data acquisition and analysis would add 
further value to studies performed by expert groups 5-8. While some suggestions and 
recommendations have appeared in the literature in recent years 9-12, we believe it is crucial define 
the conditions to standardize the evaluation of LV function in small rodents using echocardiography. 
Standardized and well-defined echocardiographic conditions will aid both authors and reviewers in 
evaluating the accuracy of cardiac function data derived from small rodents. 
This paper also includes reference values for adult mice and rats (Tables 1 and 2), echocardiographic 
routines for assessing specific pathologic conditions (Table 3), common pitfalls to avoid in the 
echocardiography of rodents, and reference to scientific literature for specific methodological 
details. Although we could not include all publications available in this expanding field, 
representative studies supporting our statements have been cited. 
 
1. Minimal requirements for echocardiographic evaluation in rodents 
Considerable progress in technology and equipment have made the detailed evaluation of cardiac 
structure and function possible in small rodents. While pioneering studies used clinical 
echocardiographic systems 13, modern and high-frequency instruments specifically designed for 
small animal hearts are now available and capable to acquire both improved high-frame-rate and 
near-field images 14, 15. For echocardiography in mice, we recommend transducers with a center 
frequency of at least 30 MHz (body weight >35 g) or 40 MHz (body weight <35 g), with a real-time 
imaging frame-rate of more than 30 frames per heartbeat 16. For advanced image analysis, such as 
speckle tracking or myocardial strain, frame-rates of 100 frames per heartbeat are recommended 
in mice 17. For Doppler studies, the ultrasound (US) probe should be capable of recording a peak 
velocity higher than 1500 mm/s in mice. Currently, echocardiographic images in rats can be 
obtained using conventional frequencies in the 10-15 MHz range 18. However, advances in dedicated 
small animal echocardiography can lead to improved image quality using higher frequencies. 
Additional equipment is essential for the echocardiographic exam, i.e. electrocardiography (ECG) 
electrodes connected to the US machine, a temperature probe. and either a heating pad or a heat 
lamp source, to maintain the animal’s physiological body temperature. Furthermore, a vaporizer is 
required to administer volatile anesthetics, and limited ambient light during the acquisition is 
recommended to obtain optimal contrast. 
 












A few studies encourage performing echocardiography in conscious rodents after acclimatizing 
them to the researcher and the environment19. However, unlike humans and large animals, 
echocardiography without anesthesia is highly stressful for rodents, leading to variations in stress 
response between groups that might mask pathology-induced differences, particularly in diastolic 
function assessment. In addition, working with conscious animals can often also be very stressful 
for the researchers. Thus, we recommend anesthetizing the animals to increase the reproducibility 
of the measurements and to reliably compare data obtained between groups 11, 20. However, it 
should be taken into consideration that the induction of the anesthesia might vary significantly with 
age, strain, liver/lung function, obesity, and other diseases such as heart failure (HF), sepsis, etc. For 
instance, special attention should be given to models of ischemia/reperfusion, wherein some 
anesthetics, such as halogenated gases and opioids, have been shown to interfere with 
cardioprotection 21, 22. Supplementary Table 1 provides reference values for conscious mice, to be 
adopted if the experimental conditions require avoiding the use of any type of anesthesia. 
Most anesthetics have negative inotropic and chronotropic effects. For instance, tribromoethanol 
(e.g. Avertin™), pentobarbital (e.g. Eutha 77™) and ketamine (e.g. Ketaset™) have all shown to 
depress cardiac function. The most popular anesthetics are either a mixture of ketamine/xylazine 
(e.g. Rompun™; 100/10 mg/kg i.p., respectively) or halogenated gases, such as isoflurane (1-2%)11, 
18, 23 and sevoflurane (3-4%) 24.  These gases should be delivered in 21% oxygen and 79% nitrogen 
mixture 25, 26, although an oxygen-enriched gas mixture is widely used and accepted. While ketamine 
is the only anesthetic that increases blood pressure and heart rate (HR) 27, its combination with 
xylazine results in cardio-depression. On the contrary, halogenated gases are now preferred, due to 
their easy titration, fast reversibility and, most importantly, minimal cardiovascular depression. For 
a more detailed overview of the advantages and limitations of the most common anesthetics used 
during echocardiography in mice, see Lindsey et al. 9, 10. In rats, ketamine/xylazine and isoflurane 
are among the most commonly used anesthetics during echocardiographic acquisition. Their 
comparison has been essentially performed in healthy rats, in which cardio-depressive effects, 
without changes in systolic and LV dimension indexes, were induced by ketamine/xylazine but not 
by isoflurane 28-30. Although useful, the uptake and/or effect of anesthetics in diseased rats might 
differ. While further research is required to precisely determine the effects of different anesthetics 
on hemodynamic, systolic, LV dimension, and diastolic indexes in both mice and rats, this position 
paper suggests the use of halogenate gases as the first-line choice for rodent echocardiography.  
2.2. Monitoring physiological parameters 
Cardiac function depends on multiple physiological parameters, including HR, body temperature, 
respiratory rate, blood pressure and oxygenation levels, which are all influenced by most 
anesthetics. Although the instrumentation and expertise to accurately monitor blood pressure and 
oxygenation levels in rodents is not available in most laboratories, body temperature, HR and 
respiratory rate can be easily monitored during rodent echocardiography. While blood pressure and 
oxygenation levels provide a direct measure of potential anesthetic cardio-depressant actions, body 
temperature, HR, and respiratory rate provide an indirect estimate of the impact that changes in 
the autonomic nervous system might impose during the exam. Body temperature can be measured 











heating pad. Anesthetized animals are unable to control and maintain their physiological body 
temperature, which is a major determinant of several cardiovascular function indexes. Rats, in 
particular, are at higher risk for hypothermia due to their high body surface to body mass ratio. In 
addition to anesthesia, the resting-state, shaving, and application of echocardiography gel further 
increase the risk of hypothermia. As such, continuous monitoring of body temperature by a rectal 
probe is recommended to regulate the heating and maintain the body temperature.  
HR can be monitored by ECG, either by taping electrodes to the paws or laying the animal on a 
platform equipped with electrodes. When monitoring the HR, differences between strains 31-33 and 
specific experimental conditions can have a major impact and should be considered when 
performing echocardiography. When starting the measurements, the transducer should be covered 
by warm gel and applied gently to avoid chest compression, thereby minimizing cardiovascular 
reflexes, such as bradycardia and hypotension. For the most commonly used rodent models, any 
intervention/anesthesia lowering the HR to values below 450 beats per minute (bpm) in mice and 
350 bpm in rats is considered to exert cardio-depression, i.e. concomitant negative inotropic and 
chronotropic effects. This compromises the reliability of cardiac parameters assessed, as shown in 
Table 2, in which reference values are split in separate columns for mice kept at a physiological HR 
( 450 bm) or depressed by anesthesia (HR < 450 bpm). While we believe that this threshold should 
be applied to most studies to ensure the contextual evaluation of both systolic and diastolic function 
(see also below), a lower HR could be acceptable in experimental settings that result in decreased 
basal HR, e.g. in the presence of a beta-blocker. However, in such studies, authors should provide 
an explanation as to why HR is low. In any case, consistency of HR values between experimental 
groups has to be demonstrated and HR values should always be reported together with the 
functional measurements.  
A description on how to start and finalize the echocardiographic exam is depicted in Figure 1. 
 
3. Echocardiographic techniques 
Similar to humans, echocardiography imaging in rodents can incorporate five main modalities, in 
several views and planes: i) motion mode (M-mode), ii) two-dimensional (2D) brightness mode (B-
mode), iii), Doppler imaging, iv) speckle tracking echocardiography (STE), and v) three/four-
dimensional (3D/4D) imaging.  
 
3.1. M-mode  
The M-mode can be used for the assessment of systolic function and LV size. M-mode tracing can 
be performed in either the parasternal long- or short-axis (Figure 2). To obtain a parasternal long-
axis of the heart, the animal is laid in a supine position and the US transducer should be placed on 
the left side of the animal’s chest, with the notch pointed toward its right shoulder. The following 
features should be considered as indicators of an appropriate long-axis view: i) the aortic valve, the 
proximal course of aortic root and ascending aorta and the left ventricle apex are visible; ii) the LV 
is positioned in the center of the field of view; iii) the base-to-apex axis is parallel to the transducer 
surface, corresponding to the longest axis (Figures 2 and 3). Usually, the right ventricle (RV) can be 
partially seen in this view. From this position, a 90° rotation of the transducer clockwise generates 











papillary muscles, which should be simultaneously visible in the antero-lateral and postero-medial 
quadrants of the heart, respectively 34. In the short-axis view, the LV should have a round shape, 
which should be maintained while moving through the long-axis of the LV from base to apex (Figures 
2 and 3). If it appears oval, the LV is most likely being imaged obliquely. Common pitfalls include, 
but are not limited to, off-axis views, inclusion of RV trabeculae as part of the septum, and acquiring 
a short-axis recording at the papillary muscle rather than the posterior wall (Figure 3). 
3.2. B-mode  
The B-mode can be applied to all echocardiographic views. Together with a four-chamber view, the 
parasternal long-axis view can be used in rodents for studying LV volumes and function. While in 
humans the LV apex is not included in parasternal long-axis view and is commonly visualized in 
either the four- or the two-chamber view, the larger size of the transducer, relative to the size of 
the heart, permits good visualization of the apex together with basal and medium segments of the 
anteroseptal and posterior LV wall in rodents (Figure 2). Particular attention should be taken to 
avoid foreshortened or truncated views with a ‘false’ apex, as could be suggested by a spherical, 
not elliptical, shape of the LV (Figure 3). Based on the parasternal long-axis view, as described in 
Section 3.1, LV images are extracted from the cine-loop recordings at the end of both systole and 
diastole. These specific time points are recognized as optimal if the ECG is simultaneously recorded 
and displayed 35. Here, the end of the diastole corresponds to the frame in which the LV reaches its 
maximal extension (LVEDA, LV end-diastolic area), whereas the end of systole corresponds to the 
minimal size of the LV area (LVESA, LV end-systolic area). 
B-mode imaging is also frequently used for multiplane evaluations for several purposes, such as 
assessment of valve function, cardiac output, vessel size, and more accurately measured LV 
volumes (using a modified Simpson’s rule as described below36). This approach combines the 
measurements taken from multiple views, including the parasternal long-axis and at least three 
short-axes i) at the level of the base, ii) at an intermediate position, approximately at the level of 
the papillary muscles, and iii) at the apex level (Figures 2 and 4). 
3.3. Doppler analysis 
Pulsed-wave (PW) Doppler is used to assess the myocardial and flow-velocity profiles of moving 
objects or structures, which are particularly useful in assessing diastolic function. It is based on the 
Doppler principle, by which wave frequencies change every time they are reflected by moving 
targets. For instance, when the reflected waves are moving toward the receiver, each successive 
wave is reflected from a position closer to the receiver than the previous one. Hence, the time 
between the arrivals of successive waves at the observer is reduced, causing an increase in their 
frequency. Conversely, if the target is moving away from the receiver, each wave is reflected from 
a position farther from the receiver than the previous one, so the arrival time between successive 
waves is increased, reducing the frequency. This is why any change in blood flow velocity can be 
appreciated as a Doppler shift 10, 24. 
In humans, Doppler shift can be assessed either continuously, when two separated transducers 
simultaneously emit and receive Doppler signals, or pulsed, when the same transducer alternatively 
emits and receive the signals in a pre-specified volumetric region or scan line. Color Doppler 
indicates the mean velocity in discrete ranges, which are displayed in different colors. Any 











transducer are indicated in red. In rodents, PW and color Doppler are commonly used to display the 
velocity of moving objects inside the heart and blood vessels. In the case of PW and color Doppler, 
the moving objects are blood cells, while in tissue Doppler Imaging (TDI), the moving target is the 
myocardial tissue. In both cases, the user has to select the targeted sample blood/myocardial 
volume by placing the sample volume over this area, and to ensure that the Doppler beam is aligned 
with the direction of the moving objects to avoid underestimation of their velocity 10, 24. Special 
attention should be given to the position of the sample volume, as missing the highest velocities 
seems to be one of the most common pitfalls in assessing diastolic function in rodents (Figure 3). 
Compared to blood, the velocities of the moving tissue are much lower and the amplitude of the 
backscattered signal from tissue is much larger, therefore the velocity scale must be reduced to 
values near the 30-60 mm/s and the gain minimized. Myocardial movement analysis by TDI presents 
some limitations, in that myocardial structures are constantly moving longitudinally and 
circumferentially, and passive motion is difficult to separate from active movement.  
Usually, PW and TDI analysis are performed at the four-chamber view, which can be obtained by 
placing the transducer over the apex and pointing it medially towards the animal’s head, so that 
the beam crosses both ventricles, both atria, and their respective walls and septa. This view enables 
both a good orientation of a Doppler mitral and tricuspid flow signal and the acquisition of tissue 
Doppler signals near the mitral and tricuspid valve annuli 24. Again, placing the sample volume in 
the optimal position guarantees the acquisition of maximal velocities.  
3.4. Speckle Tracking Echocardiography  
Modern small animal instrumentation allows the visualization of myocardial deformations by 
speckle tracking echocardiography (STE) and quantitative evaluation of both global and regional 
myocardial function, independently from both insonation angle and cardiac translational 
movements 37. As in humans, accurate STE acquisition in animal models requires images with a 
clear visualization of both endocardial and epicardial borders and a high frame rate (at least 100 
frames per heartbeat) 17. 
Several tracking points should be placed on the endocardial border to semi-automatically trace the 
endocardial and epicardial border, in both long and short-axis views at the level of the papillary 
muscles. Both axes are automatically divided in multiple segments for the quantification of: i) 
displacement, which defines the distance that each point has moved between two consecutive 
frames, ii) velocity, which reflects displacement per unit of time, iii) strain, which reflects the 
deformation of an object normalized to its original shape and size, and iv) strain rate, which 
describes the rate of strain or in other words how fast the deformation occurs. Strain and strain 
rate are preferable to velocity and displacement data, as the recording of velocity and displacement 
is influenced by movements of the chest during breathing, while strain and strain rate are not. 
These parameters allow the discrimination of myocardial active and passive movements, and the 
separate assessment of distinct components of myocardial deformation, such as lengthening, 
shortening, thickening, twisting and torsion 38. Thus, more complex geometric aspects are 
implicated in the estimation of LV contractility by STE compared to standard echocardiography 39. 
Values of strain and strain rate can be obtained for the longitudinal, radial, and circumferential 











In humans, global longitudinal strain, obtained as the average of the longitudinal strain of each 
myocardial segment recorded from the three apical views, is the most accepted and studied STE-
derived parameter of systolic function 40. Due to its ability to detect and quantify local impairments 
in cardiac contractility, STE is widely used in the clinics, particularly to detect subclinical stages of 
myocardial dysfunction in a broad range of pathologies that have not yet resulted in increased 
volumes or compromised EF. These include: i) the detection of small, recent and sub-endocardial 
myocardial infarction 17, 41-45 , ii) the detection of subtle systolic dysfunction in patients with heart 
failure with preserved ejection fraction (HFpEF) 46-48, iii) the discrimination between physiological 
and pathological LV hypertrophy 49, iv) the early diagnosis of chemotherapy-induced cardiac toxicity 
50-53, and v) the identification of sub-clinical cardiac dysfunction in relatives of patients affected by 
genetic forms of dilated cardiomyopathy 54, 55. 
While STE is becoming more widely used, most of the rodent studies published in high-impact 
journals of general interest do not include strain analysis 56-66. Since all US-based images have better 
resolution if acquired along the US beam, STE is not completely angle-independent 67 and values 
obtained in the parasternal long-axis view in rodents may be less accurate compared to those in 
humans. An additional, current limitation is the absence of reference values, the definition of which 
will require more widespread use of this technology in animal models to ensure reproducibility and 
accuracy. Examples of STE in healthy, hypertrophied and infarcted hearts are depicted in Videos 1-
6. 
3.5. Three/four-dimensional (3D/4D) imaging 
Modern instrumentation for both human and small animal echocardiography allows the 3D 
volumetric reconstruction of cardiac chambers. The software analyzes LV geometry (volume and 
mass) upon the acquisition of multiple serial images at a pre-defined distance (micrometric slices), 
using a motor that moves the transducer along the long-axis. These slices can be eventually merged 
and combined with a temporal dimension (4D) through automated respiratory and ECG gating. 
Volumes at late systolic and diastolic time points are acquired as post-processing analysis. 
Theoretically, 3D/4D imaging appears as the most reliable method for assessment of cardiac 
chamber volume and function, being based on real, imaged-based endocardial and epicardial 
tracing and not on geometrical assumptions. The additive value of 3D/4D imaging over B-mode 
single- and multi-plane methods for the evaluation of volumes and systolic function and its 
comparison with the gold standard magnetic resonance imaging (MRI) has been demonstrated by 
a few pioneering studies in rodents 68, 69. It has also been applied to genetic models of cardiac 
dysfunction. However, this echocardiographic technique has several limitations, including the need 
for accurate ECG and respiratory gating by sophisticated equipment (often not available in standard 
laboratories), the generation of extensive data, requiring powerful computational resources for 
analysis, and moderate reproducibility 69. While anatomic structures (i.e. ribs, sternum, lungs) could 
interfere with 3D heart reconstruction, the relatively low cost, rapid acquisition time, and high 
spatiotemporal resolution are expected to promote the use of 3D/4D echocardiography for the 
evaluation of LV function in small animals. 
While reference values for 3D/4D-generated data on human cardiac dimensions and mechanics 
have recently been provided 40, large databases have not yet been built for rodents and it is 











hearts subjected to chronic pressure overload and myocardial infarction are provided (Videos 7-9, 
respectively).  
 
4. Evaluation of systolic function 
To evaluate systolic function in rodents, three major imaging views are used: M-mode single-plane 
evaluation, and B-mode single- and multi-plane evaluation. 
4.1. M-mode (single-plane) parasternal short-axis view 
M-mode tracing on the short-axis has been the most commonly used method to measure systolic 
function in both mice and rats 56-66, 70, 71. M-mode images are displayed as a continuous function of 
time, allowing optimal temporal resolution and precise quantification of wall thickening 72. 
Measurements have to be taken in both systole and diastole, which requires simultaneous ECG 
recording. The start of the QRS complex on the ECG marks the end of diastole, the time point at 
which diastolic measurements should be acquired. Systolic measurements can be made at either 
the zenith of the posterior wall motion or the nadir of the anterior wall motion. These two events 
do not occur exactly at the same time, neither in humans nor in rodents. However, they can both 
be used as a reference for systolic measurements with the same level of accuracy, which results in 
comparable values. In the case of a large myocardial infarction, the anterior wall motion is often 
compromised and the use of the posterior wall peak motion is recommended.  
The leading edge method, in which measurements are calculated from the side closest to the 
transducer towards the leading edge of the following echo, allows the quantification of the following 
LV parameters both in systole and diastole (Figure 2): anterior wall thickness (LVAWs and LVAWd), 
posterior wall thickness (LVPWs and LVPWd), and internal diameters (LVIDs and LVIDd) 73. From 
these values, fractional shortening (FS), LV end-systolic and end-diastolic volumes (LVESV and 
LVEDV), and ejection fraction (EF) can be calculated, applying the following formulas 74: 
FS (%) = (LVIDd – LVIDs)/LVIDd x 100 
LVESV = (7/(2.4 + LVIDs)) x LVIDs3 
LVEDV = (7/(2.4 + LVIDd)) x LVIDd3 
EF (%) = (LVEDV - LVESV)/LVEDV x 100 
However, since M-mode tracing records cardiac contraction on a single spatial plane, these 
calculations rely on geometrical and mathematical assumptions that do not exactly represent the 
shape of the heart. In particular, the change in volume during systole and diastole derives from 
linear changes measured on the short-axis, without any contribution from longitudinal contraction. 
Moreover, the shape of the LV is assumed to be a modified ellipsoid, whereas the physiological LV 
often has an irregular shape, particularly after myocardial infarction, asymmetric septal hypertrophy 
or RV failure 36. 
Furthermore, it should be taken into account that any error in the tracing significantly reduces the 
accuracy of the data, as the measurements are raised to the third power for the calculation of LV 
volumes. Finally, the accuracy of this method is further limited in case of segmental wall motion 
abnormalities, i.e. in the post-myocardial infarction, particularly at the apex. Therefore, B-mode 
evaluation is preferred to properly evaluate systolic function in most experimental models. 
LV mass can be estimated using Devereux’s formula 75, modified for rodents: 











The formula to calculate LV mass is derived from the formula applied in humans, where 1.04 is the 
estimated specific gravity and the remaining constants are correction factors. Importantly, the 
values of LV mass significantly correlate with post-mortem LV weight in normal Sprague-Dawley rats 
76 and hypertensive Dahl-salt rats 77.  
Another option when computing LV mass is by using the less common area-length method 78. 
Although it seems more accurate, it warrants validation to determine the degree of correlation with 
LV weight or LV mass assessed by 3D-echocardiography. In a simplistic view, LV mass is estimated 
by subtracting the volume of an ellipse corresponding to the LV cavity from the total LV volume (wall 
+ cavity). To accomplish this, one should trace the epicardium and endocardium in midventricular 
parasternal short-axis view, calculate the average myocardial wall thickness ((LVAWd + LVPWd) / 2), 
and apply the following formula: 
LV mass = 1.05 x [5/6 x EpiC x (LVEDL + (LVAWd + LVPWd) / 2)] – (5/6 x EndC x LVEDL) 
where EpiC, and EndC correspond to epicardial and endocardial areas in diastole, respectively, and 
LVEDL is the end-diastolic LV length, corresponding to the distance from the aortic annulus to the 
endocardial border of the apex (measured in B-mode, long axis). 
4.2. B-mode (single-plane) parasternal long-axis view  
Aortic diameter and left atrial (LA) area can be measured in parasternal long-axis orientation using 
the B-mode, although we recommend measuring LA area in the four-chamber view. Tilting the 
transducer slightly in this position reveals the RV and pulmonary artery, thereby allowing 
assessment of the total RV and RV outflow tract dimensions in M-mode, as well as the pulmonary 
velocity-time integral (VTI) using PW Doppler. 
Using a mono-plane of the parasternal long-axis view in B-mode, a significant number of systolic 
indexes and volumes can be obtained. This is achieved by tracing the endocardial border around the 
LV cavity at the end of both systole and diastole, thereby generating the LV end-diastolic and end-
systolic area (LVEDA and LVESA, respectively) and by measuring the LV length at end-diastole and 
end-systole, respectively (LVEDL and LVESL), as shown in Figure 2 and according to the following 
formulas:  
LVEDV = 8 x LVEDA2/3  LVEDL 
LVESV = 8 x LVESA2/3  LVESL 
Based on these calculations, other systolic function parameters can be determined 79, 80, such as 
stroke volume (SV, volume of blood ejected from the LV during systole), and cardiac output (CO, 
volume of blood ejected from the LV per minute). In the case of large differences in body weight 
(BW), cardiac output should be normalized to body surface area (BSA) and expressed as cardiac 
index (CI). Below, the corresponding formulas are given: 
SV = LVEDV – LVESV 
CO = SV x HR 
CI = CO / BSA 
BSA = 9.8 x BW2/3 
Similar to M-mode images, these calculations are also based on the geometrical assumption that 
the LV has a modified ellipsoid shape 36. Again, this can generate inaccuracy, particularly when 
motion abnormalities are localized in any of the walls, which are not seen in this view.  











This approach, also referred to as the ‘Simpson’s method’, allows the measurement of ventricular 
volumes with a higher accuracy by using an approach that bears similarities with the clinical biplane 
method of disks. In this approach, the total LV volume is calculated from the sum of a stack of 
elliptical disks. From the parasternal long-axis view, LVEDL and LVESL are measured. Then, images 
of the LV in its short-axis are analyzed at the following three levels: i) at the level of the base, ii) at 
an intermediate position, approximately at the level of the papillary muscles, and iii) at the apex 
level (Figures 2 and 4). From these acquisitions, a three-dimensional reconstruction of the LV 
geometry and the calculation of diastolic and systolic LV volumes are possible using a modified 
Simpson’s rule 36, 81, 82 (also called method disks technique):  
LVEDV = (A1+A2) x (LVEDL/3) + (A3/2) x (LVEDL/3) + (π/6) x (LVEDL/3)3 
LVESV = (A1+A2) x (LVESL/3) + (A3/2) x (LVESL/3) + (π/6) x (LVESL/3)3 
where A1, A2, and A3 are LV areas at the level of mitral valve, papillary muscles and apex, in diastole 
and systole respectively. However, in pathological conditions, e.g. after myocardial infarction, 
papillary muscles might be either fibrotic and poorly visible or displaced. Thus, an appropriate and 
consistent method for standardization of the short-axis imaging is warranted. This could be achieved 
by scrolling along the long-axis to set the basal and apical views at the most distant sections in which 
the LV chamber is still visible both in systole and diastole (without the inclusion of left atrium at the 
base) and adding an intermediate recording halfway. Accurate and consistent positioning of the 
short-axis views is crucial to obtain standardized data, especially in myocardial infarction settings. 
In each plane, the endocardial border is traced at the end of both diastole and systole, as described 
above.  
Convincing evidence in both humans and rodents 83, 84 has shown that in pathological conditions, 
such as after myocardial infarction, this method is more accurate to quantify LV volumes and cardiac 
function compared to the M-mode, due to variable localization and the segmental nature of the 
ischemic lesion. On the other hand, this method requires adequate acoustic windows for the 
accurate visualization of the endocardial border and measurement. This is often difficult to achieve 
in rodents, in which myocardial infarction is mostly induced experimentally by surgical ligation of 
the proximal left anterior descending (LAD) coronary artery, resulting in apical lesions, which 
severely affect the definition and resolution of the endocardial border. In addition, the surgical 
procedure and the sutures on the chest further reduce the quality of the acoustic window and often 
result in major distortion of the heart’s geometry. Thus, to what extent this method is more reliable 
and accurate compared to the B-mode, single-plane evaluation of the long-axis (in which apical 
lesions can be better visualized) remains an open question.  
4.4. PW Doppler echocardiography 
PW Doppler provides hemodynamic information and more precise quantification of SV than 2D 
echocardiography 85. In particular, PW Doppler of aortic flow is used to evaluate blood flow velocity 
at the level of the LV outflow tract (LVOT) to derive the VTI. While LVOT VTI is usually assessed with 
the five-chamber view, the cross-sectional area is measured with the parasternal long-axis view in 
B-mode. SV can then be calculated by applying the following equation: 
SV = VTI x CSA  
where CSA refers to the cross-sectional area of the LVOT and can be derived by measuring the LVOT 











CSA = D2 × π/4 = D2 × 0.785 
Accurate PW Doppler measurements require that US waves are parallel to the blood flow, or that 
angle correction is implemented when the beam is not aligned with the blood flow. In humans, this 
is easily achieved by recording a PW Doppler signal at 5 mm from the aortic valve in an apical five-
chamber view 85. In mice, the parallel orientation can be better obtained at the level of the 
pulmonary artery, as the SV is equal for both ventricles (Figure 2). The reliability of PW Doppler 
echocardiography in determining CO in mice has been validated and compared to standard 
echocardiography and invasive measurements 86, showing that all US-based techniques tend to 
overestimate CO. Although B-mode single-plane evaluation provided values which are closely 
comparable to values derived by invasive assessment, VTI-derived CO assessed at the level of the 
pulmonary artery was the most reproducible method, showing the lowest interobserver variability. 
In rats, the approach is the same, but CO can be calculated from CSA and VTIs measured at the LVOT 
or at the aorta 24. 
 
5. Evaluation of diastolic function 
Diastole comprises the relaxation and filling of cardiac cavities to enable an adequate blood volume 
to maintain normal cardiac output. Diastolic dysfunction can derive from abnormal relaxation 
and/or increased myocardial stiffness of the LV, eventually leading to elevated LV filling pressures 
and HF symptoms. In the presence of either preserved or minimally depressed EF, diastolic 
dysfunction is the main determinant of HFpEF. Assessment of diastolic dysfunction is receiving 
more and more attention, as HFpEF currently accounts for nearly half of the HF patients, and its 
prevalence continues to rise due to the increasingly aged society and survival of patients with 
comorbidities for HFpEF, such as type 2 diabetes, hypertension, and obesity87. While the prevalence 
of HFpEF rises, no effective therapeutic and prevention options are available, mostly due to a lack 
of pathophysiological understanding, patient heterogeneity, and underdiagnosis 88, 89. Diastolic 
dysfunction is frequently associated with increased interstitial fibrosis, LV concentric hypertrophy, 
and atrial enlargement. Moreover, pulmonary hypertension and RV dysfunction, often arising in 
response to elevated LV filling pressure, are key hemodynamic abnormalities in diastolic 
dysfunction, which can effectively stratify HF phenotypes (with both reduced and preserved EF) 90, 
91.  
As in humans, assessment of LV diastolic function in rodents includes Doppler evaluation of LV filling 
velocity, measured by the ratio between early (E) and late (A) diastolic transmitral Doppler flow 
velocities (E/A), isovolumetric relaxation time (IVRT), mitral valve E wave deceleration time (DT), 
and LA area 92. Nevertheless, E/A and IVRT are highly dependent on the pressure gradient between 
left atrium and ventricle. With the emergence of TDI, myocardial motion in early diastole, as 
assessed by peak early-diastolic annular velocity (e’), became a good measure of diastolic function 
24. E to e’ ratio is, therefore, an appropriate estimator of LV filling pressures, that has been adopted 
as one of the criteria for clinical diagnosis of HFpEF and is successfully applied in small animal 
studies 92. Lately, the E-wave deceleration rate E/DT has been proposed, outperforming the tissue 
Doppler-derived index E/e' in characterizing lung remodeling in HFpEF 93. 
While most of the indexes of diastolic function are relatively easy to obtain in rats, their 











distinction applies for normal cut-off values, which appear highly variable in intra- and inter-strain 
comparative studies in mice 94. Conversely, reference values appear more homogeneous and 
standardized in rats (Table 1) 95, 96. Finally, while in humans, echocardiographic diastolic parameters 
have been clinically and hemodynamically validated, with E/e’ ratio values > 15 consistently 
associated with elevated LV filling pressures, this evidence has only recently been provided for rats 
97 and is still not reported for mice. While most studies provide “normal” E/e’ ratio values between 
20 and 30 98-100, it has to be emphasized that, in mice, it is very difficult to measure e’ velocity close 
to the mitral valve, often resulting in its underestimation (Figure 3).   
In view of these limitations, the following guidelines will be useful to standardize the evaluation of 
diastolic function and define universal reference values also in mice.  
5.1. B-mode, apical four-chamber evaluation  
Analysis of diastolic function should start with the B-mode to visualize the apical four-chamber view. 
Although the LA area can be measured in parasternal long-axis orientation, we recommend 
measuring it in the four-chamber view in B-Mode, assuring the simultaneous visualization of atria 
as well as mitral and tricuspid valves opening and closing (Figure 2). LA maximal extension should 
be confirmed by observing cine-loop recordings. Indeed, the LA area has been routinely used as a 
marker for chronic elevation of LV filling pressure and diastolic dysfunction in both humans and 
animal models 92, 101.  
Apart from diastole, if one aims to evaluate valvular function, this plane also allows a suitable 
alignment of mitral and tricuspid annuli to assess their motion in M-mode. Slightly tilting the 
transducer down enables a five-chamber view, where the left ventricular outflow tract and aorta 
are revealed (Figure 2). 
5.2. PW and Tissue Doppler in apical four-chamber evaluation 
The apical four-chamber view represents the preferred plane for recording transmitral Doppler 
flows (E and A velocities, their ratio, DT, and IVRT) and TDI imaging (e’, a’, and s’) with the sample 
volume placed at the tips of the mitral leaflet and at the lateral mitral valve annulus, respectively. 
The E wave represents the transmitral blood flow during the LV early filling phase and can be 
affected by the rate of LV relaxation and its compliance. The A wave represents the transmitral 
blood flow during the atrial contraction phase and can be altered by LA contractility or compliance 
102. The E/A ratio provides important information about LV filling dynamics 24. Special attention 
should be given when assessing these velocities, as they are highly dependent on HR, and thus 
anesthesia. Preferentially, these measurements should be acquired with other more reliable 
parameters, such as annular tissue velocities and LA size 102. Other diastolic parameters include DT, 
the duration of E wave peak to the baseline, and IVRT, which is the time from the closure of the 
aortic valve to the opening of the mitral valve. Increased IVRT and DT reflect a prolonged LV 
relaxation, but can both be influenced by a number of factors, such as preload, arrhythmia or very 
high HR, as well as diseases that cause hyperdynamic states. 
During TDI, early (e’) and late (a’) diastolic mitral annulus peak velocity and systolic peak wave can 
be assessed. The e’ velocity is determined by LV relaxation, restoring forces, and filling pressures. e’ 
velocity has been shown to correlate well with invasive measures of IVRT constant of myocardial 
relaxation, tau 103. The mitral E/e’ is proposed to reflect LA pressure, and, indirectly, LV end-diastolic 











function 104. Currently, an elevated E/e’ is proposed as a guideline for the diagnosis of diastolic 
dysfunction 105. However, under certain conditions, including (i) tachycardia with fusion of E and A 
velocities, (ii) unreliable measurement of E velocity (significant mitral regurgitation), (iii) unreliable 
e’ velocities (e.g. mitral valve replacement, mitral annular calcification, mitral stenosis, and/or left 
bundle branch block), and/or (iv) significant aortic regurgitation, precautions should be taken with 
regard to the use of E/e’ as a marker for diastolic dysfunction 106. For the acquisition of TDI, the gain 
should be considerably adjusted to avoid superimposition of multiple amplitudes. Furthermore, it is 
important to position the sample volume at the myocardium, as close as possible to the mitral or 
tricuspid annuli to assess the areas with greater excursion enabling the recording of maximal 
velocities with a better temporal resolution 24. Measurements acquired in myocardial areas distal 
to the ones herein recommended will result in lower velocities and increased E/e’ values (Figure 3).  
At heart rates > 450 bpm, E and A waves are frequently merged. Some authors suggest to artificially 
reduce heart rate by increasing anesthesia proportionally in all groups. We argue that this is not 
physiological and should be avoided. Instead, one should try to extract E-wave velocity peak value 
and normalize it to e’. Indeed, E/e’ represents a much more reliable parameter to assess diastolic 
function when compared to E/A, since it has an excellent correlation with LV end-diastolic pressure 
(LVEDP, indicative of myocardial stiffness) and tau 23, 94, 103. Other echocardiographic indexes have 
been proposed as surrogates of LVEDP, such as E/DT, after normalizing DT to cardiac cycle duration 
97. 
Both PW and TDI allow extracting the values of isovolumetric contraction time (IVCT), IVRT and 
ejection time (ET) as shown in Figure 2. From these, one can derive Myocardial Performance Index 
(TEI Index) 107: 
TEI = (IVCT + IVRT) / ET 
We should emphasize that while IVRT is a diastolic parameter, TEI index assesses myocardial global 
function, including both diastolic and systolic function. The underlying rationale is that both 
isovolumetric periods, IVRT and IVCT, are energy-dependent but do not produce work. Myocardial 
dysfunction usually prolongs the isovolumetric periods, yielding higher values for this index 
compared to a healthy heart. 
Finally, as mentioned earlier, several studies have established an independent relationship 
between RV dysfunction and the prevalence and prognosis of HFpEF, using feasible and readily 
available echocardiographic measurements 90, 91. Tricuspid annular plane systolic excursion (TAPSE) 
reproduces well the degree of RV longitudinal contraction and has proven to be a reliable 
parameter to assess global RV function (Figure 2). TAPSE is measured in the apical four-chamber 
view and the M-mode cursor should be positioned on the lateral tricuspid annulus near the free RV 
wall and aligned as close as possible to the apex of the heart. Special care should be taken in 
assuring the RV is clearly visualized in the M-mode view. Maximal TAPSE is defined by the total 
excursion/distance between the ventricle end-diastole and end-systole 108. 
 
6. Assessment of LV function in animal models of disease 
A brief description of the echocardiographic views, modalities and derived parameters for common 
cardiovascular diseases, including chronic pressure overload, myocardial infarction and diastolic 











by chronic pressure-overload and myocardial infarction, in comparison to normal, healthy hearts, 
are provided in Figure 4. In diseased conditions, the echocardiographic examination may be limited 
by poor window size and image acquisition due to the positioning of the ribs or to the presence of 
abundant fat tissue inside and around the thoracic cavity. Indeed, fat is very echogenic, i.e. US are 
easily reflected, attenuated and slowed down through the fat layer, which impairs the quality of 
the images. In addition, anesthetic induction and maintenance can vary significantly due to 
adiposity, causing differential degrees of cardio-depression.  
As mentioned above, surgical models require the use of sutures that significantly compromise the 
quality of the acoustic windows. Post-intervention fibrosis may accumulate around the heart 
further diminishing the quality of the echocardiographic images. In addition, fibrosis can induce a 
slight rotation or distortion of the heart, which may demand a corresponding corrective rotation of 
the transducer. 
Despite these limitations, echocardiography remains an invaluable tool to assess LV function in 
animal models of human diseases, that follows the principles of the 3Rs (refine, reduce and replace). 
Furthermore, it allows assessing longitudinal progression over time, i.e. at different ages in the same 
animal, as it is neither painful nor invasive (as compared to pressure/volume loop method for 
example), and therefore suitable to refine and reduce the number of studied animals. Moreover, as 
it has an extensive application in human diagnostics, echocardiography is a continuously evolving 
technique. 
 
7. Data analysis 
When analyzing echocardiographic data, one should: 
1. Register anesthetic parameters. 
2. Acquire and analyze data blindly (as echocardiographic analysis is subjective and researcher-
dependent, the data should be analyzed by multiple researchers and averages should be 
recorded).  
3. Record and present HR. 
4. Extract diastolic and systolic volumes from the same cardiac cycle. 
5. Average measurements from at least three different cycles. 
6. Calculate indexed values whenever the animals show large differences in BW (CI, EDV and ESV). 
In this case, values should be normalized to BSA defined as 9.8*BW2/3 79, 80. This applies mostly 
to volumes, dimensions and LV mass. 
7. Record and store measurements as well as cine-loop recordings. Ensure that a working-station 
is available to analyze the data off-line, without occupying the equipment.  
 
8. Conclusions 
Echocardiography is not an automated procedure and it is highly operator-dependent, relying on a 
proper acquisition and interpretation of the results by an examiner who is familiarized with both its 
capabilities and its limitations. We believe therefore that some minimal requirements need to be 
defined and followed by experimental researchers to increase the reliability of the data reported in 











This paper provides a list of standards, which should be met in order to evaluate LV function in 
rodents. We also provide a list of common pitfalls during basic echocardiographic examination 
(Figure 3). Briefly, animals should be sedated with the minimal dose of anesthesia, whenever 
possible through inhaled halogenated gases, keeping the core body temperature around 37°C and 
HR above 350 bpm in rats and 450 bpm in mice. In any case, the name and dose/concentration of 
the anesthetic, the HR and the body temperature should be clearly indicated. 
Systolic function should be assessed on B-mode images, using either single- or multi-plane 
evaluation. Experimental studies comparing the efficacy of these two methods in estimating cardiac 
volumes, as precisely determined by invasive hemodynamic monitoring, are highly encouraged and 
should provide a definitive answer regarding the optimal method to be followed in diverse models 
of heart disease (i.e. segmental versus global systolic dysfunction). In any case, a detailed 
description of the method used to calculate systolic function must be provided. M-mode evaluation 
should be limited to LV diameters and FS. Volume extrapolation is not accurate and should therefore 
be discouraged when evaluating systolic function, as already repeatedly recommended in clinical 
use 40, 109. Analysis should, preferentially, be performed post-acquisition by blinded operators, and 
the measures to ensure blinding should be clearly indicated.  
 
Diastolic function should be evaluated on B-mode images, mostly using the apical four-chamber 
view. Analysis should start by measuring LA area, followed by recording transmitral PW Doppler 
flows and TDI imaging to obtain E/A, E/e’, IVRT and DT values. Of these, enlarged LA size (in both 
mice and rats) and increased E/e’ (in rats) appear as the most reliable parameters to indicate 
elevated LV filling pressures. As in humans, diastolic dysfunction in rodents should be determined 
and proven by simultaneous alteration of multiple indexes, although definitive cut-off values still 
need to be determined.  
In addition to these methodological standards, more active interaction and discussion between 
experimental researchers and clinical sonographers should be encouraged to increase awareness of 
the morphological features of the heart in healthy and diseased conditions, as well as to import the 
most recent advances in echocardiographic tools and software to laboratory settings. 
Standardization of echocardiography, a non-invasive, inexpensive, widely available, and repeatable 
technique, would likely improve the translation from small animals to the clinic. Furthermore, as 
patients are often diagnosed once they have an established disease, standardization of 
echocardiography could help to find earlier characteristics of disease, which would improve the 
diagnosis at an earlier stage in humans. 
Various publications and databases are available and provide reference values for echocardiography 
measurements and calculations derived from different strains and genders of mice and rats 28, 110-
112. As these normal values have not been obtained using a standardized approach, Tables 1 and 2 
provide a summary of reference values obtained in our laboratories, following the 
recommendations listed in this manuscript, for the most commonly used rodent strains and 
anesthetics. Inexperienced sonographers are encouraged to refer to these data to match the 
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Figure 1: Recommendations for preparing the animal and finalizing the echocardiographic exam. 
Do not forget to register: 1) mouse/rat strain, sex, age and weight; 2) equipment used (model and 
probe) and 3) anesthesia type and dose. 
Figure 2: Standard echocardiographic views. For each projection, we describe the parameters 
that should be measured as well as its derived parameters. A, late diastolic transmitral flow 
velocity; AV, aortic valve; CO, cardiac output; DT, deceleration time; E, early diastolic transmitral 
flow velocity; e’, peak early-diastolic annular velocity; EF, ejection fraction; FS, fractional 
shortening; HR, heart rate; IVRT, isovolumic relaxation time; IVSd, interventricular septum 
thickness in diastole; IVSs, interventricular septum thickness in systole; LAA, left atrial area; LV, left 
ventricle; LVEDV, left ventricular end-diastolic volume; LVEDA, left ventricular end-diastolic area; 
LVESA, left ventricular end-systolic area; LVESV, left ventricular end-systolic volume; LVIDd, left 
ventricle internal diameter in diastole; LVIDs, left ventricle internal diameter in systole; LV mass, 
left ventricle mass; LVAWd, left ventricular anterior wall thickness in diastole; LVAWs, left 
ventricular anterior wall thickness in systole; LVPWd, left ventricular posterior wall thickness in 
diastole; LVPWs, left ventricular posterior wall thickness in systole; MPI, myocardial performance 
(Tei) index; RA, right atria; RV, right ventricle; RWT, relative wall thickness; s’, peak systolic annular 
velocity; SV, stroke volume; VTI, velocity time integral; PW, pulsed wave.  
Figure 3: Common pitfalls when assessing systolic and diastolic function in HFrEF and HFpEF 
animal models. LV, left ventricle; PA, pulmonary artery; pv, pulmonary valve; pm, papillary 
muscle; IVS, interventricular septum; RV, right ventricle; LA, left atrium; mv, mitral valve; MV A, 
late diastolic transmitral flow velocity; a’, late early-diastolic annular velocity; MV E, early diastolic 
transmitral flow velocity; e’, peak early-diastolic annular velocity; IVRT, isovolumic relaxation time; 
IVCT, isovolumetric contraction time; AET, aortic ejection time; HR, heart rate; bpm, beats-per-
minute. Echocardiographic exams were performed using a Vevo 3100 Imaging System 
(VisualSonics). 
Figure 4: Longitudinal and short-axis views in healthy and pathological conditions. All the 
acquisitions were made at end-diastole as determined with ECG and respiratory tracing (movies 
corresponding to each image, showing physiological parameters, are included as Supplementary 












Legend to the graphical abstract 
 
Graphical abstract – workflow of an echocardiographic exam. For each projection, we describe 
the parameters that should be measured as well as their derived parameters. A, late diastolic 
transmitral flow velocity; AV, aortic valve; CO, cardiac output; DT, deceleration time; E, early 
diastolic transmitral flow velocity; e’, peak early-diastolic annular velocity; EF, ejection fraction; FS, 
fractional shortening; HR, heart rate; IVRT, isovolumic relaxation time; IVSd, interventricular 
septum thickness in diastole; IVSs, interventricular septum thickness in systole; LAA, left atrial 
area; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEDA, left ventricular end-
diastolic area; LVESA, left ventricular end-systolic area; LVESV, left ventricular end-systolic volume; 
LVIDd, left ventricle internal diameter in diastole; LVIDs, left ventricle internal diameter in systole; 
LV mass, left ventricle mass; LVAWd, left ventricular anterior wall thickness in diastole; LVAWs, 
left ventricular anterior wall thickness in systole; LVPWd, left ventricular posterior wall thickness 
in diastole; LVPWs, left ventricular posterior wall thickness in systole; RV, right ventricle; s’, peak 
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Table 1. Echocardiographic parameters and indexes of LV function in control/healthy Wistar Han rats comparing two 
types of anesthesia. Acquisitions were made with a GE Vivid 7 system or a Siemens Sequoia using a 12MHz transducer, 
in over 100 animals. Values are presented as mean ± SD. A, late diastolic transmitral flow velocities; BW, body weight; 
CO, cardiac output; E, early diastolic transmitral flow velocities; e’, peak early-diastolic annular velocity; EF, ejection 
fraction; FS, fractional shortening; HR, heart rate; IVRT, isovolumic relaxation time; IVSd, interventricular septum 
thickness in diastole; IVSs, interventricular septum thickness in systole; LAA, left atrial area; LVEDV, left ventricular end-
diastolic volume; LVESV, left ventricular end-systolic volume; LVIDd, left ventricle internal diameter in diastole; LVIDs, 
left ventricle internal diameter in systole; LV mass, left ventricle mass; LVPWd, left ventricular posterior wall thickness 
in diastole; LVPWs, left ventricular posterior wall thickness in systole; MPI, myocardial performance (Tei) index; s’, peak 
systolic annular velocity; SV, stroke volume. 
 
Anesthesia 
Halogenated gases  
(isoflurane or sevoflurane) 
(mean ± SD) 
Ketamine: Xylazine  
(75:5 mg/kg) 
(mean ± SD) 
BW (g) 382 ± 26 364 ± 44 
HR (bpm) 383 ± 33 340 ± 10 
LVmass (mg) 645 ± 93 745 ± 30 
LVPWd (mm) 1.44 ± 0.17 1.60 ± 0.23 
LVPWs (mm) 2.23 ± 0.40 2.56 ± 0.51 
LVIDs (mm)  4.03 ± 0.40 3.53 ± 0.67 
LVIDd (mm) 6.88 ± 0.44 6.73 ± 0.43 
IVSd (mm) 1.52 ± 0.20 1.58 ±0.05 
IVSs (mm) 2.51 ± 0.42 2.63 ±0.43 
LVESV (µm)  72.3 ± 17.1 49.9 ±19 
LVEDV (µm) 247 ± 35 232 ± 34 
EF (%) 70.6 ± 5.9 79.9 ± 6.3 
FS (%) 41.4 ± 5.0 47.8 ± 7.7 
SV (µL) 175 ± 31 182 ± 24 
CO (mL/min) 68.3 ± 11.2 62.3 ± 11.6 
s’ (mm/s) 53.4 ± 9.7 58.0 ± 5.1 
E (mm/s) 774 ± 171 741 ± 155 
A (mm/s) 540 ± 136 454 ± 73 
E/A 1.44 ± 0.22 1.73 ± 0.40 
E slope (mm/s) 19.7 ± 4.5 n.a. 
IVRT (ms) 17.8 ± 4.3 16.4 ± 6.1 
MPI (Tei) 0.50 ± 0.14 0.35 ± 0.05 
e’ (mm/s) 58.0 ± 14.8 47.4 ± 11.6 
E/e’ 13.4 ± 2.2 16.7 ± 5.5 















/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvaa110/5828935 by guest on 15 M
ay 2020
Table 2. Echocardiographic parameters and indexes of LV function in control/healthy C57BL/6 mice. All acquisitions 
were made with mice under halogenated gases anesthesia (isoflurane or sevoflurane). The results presented in this 
table derive from over 300 exams performed across 10 different laboratories and are shown in separate columns for 
mice keeping HR in its physiological range (> 450 bpm) or depressed by anesthesia (< 450 bpm). Echocardiographic 
exams were made with a Vevo 770, 2100 or 3100 Imaging System (VisualSonics) or a Aloka SSD 4000. Values are 
presented as mean ±S D. BW, body weight; CO, cardiac output; EF, ejection fraction; FS, fractional shortening; HR, heart 
rate; IVSd, interventricular septum thickness in diastole; IVSs, interventricular septum thickness in systole; LAA, left 
atrial area; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVIDd, left ventricle 
internal diameter in diastole; LVIDs, left ventricle internal diameter in systole; LV mass, left ventricle mass; LVPWd, left 
ventricular posterior wall thickness in diastole; LVPWs, left ventricular posterior wall thickness in systole; SV, stroke 
volume. All values are presented as mean ± standard deviation.  
 
Anesthesia HR  450 bpm HR  450 bpm 
BW (g) 25.7±3.6 24.6 ± 2.6 
HR (bpm) 535 ± 75 418 ± 19 
LV mass (mg) 96 ± 18 99 ± 17 
LVPWd (mm) 0.79 ± 0.22 0.58 ± 0.18 
LVPWs (mm) 1.12 ± 0.33 0.84 ± 0.12 
LVIDs (mm)  2.20 ± 0.50 2.69 ± 0.39 
LVIDd (mm) 3.69 ± 0.41 3.95 ± 0.28 
IVSd (mm) 0.71 ± 0.15 0.93 ± 0.12 
IVSs (mm) 0.97 ±0.19 1.14 ± 0.14 
LVESV (µL)  19.35 ± 11.3 29.09 ± 10.4 
LVEDV (µL) 57.7 ± 16.5 66.3 ± 11.6 
EF (%) 71 ± 11 58 ± 11 
FS (%) 43 ± 9 31 ± 8 
SV (µL) 35.1 ± 8.5 31.0 ± 6.0 
CO (mL/min) 17.7 ± 3.8 14.76 
s’ (mm/s) 46 ± 7 30 ± 17 
E (mm/s) 718 ± 109 648 ± 111 
A (mm/s) 455 ± 105 427 ± 95 
E/A 1.52 ± 0.4 1.42 ± 0.26 
IVRT (ms) 17.3 ± 4.2 17.1 ± 2.5 
MPI (Tei) 0.66 ± 0.17 n.a. 
e’ (mm/s) 43.2 ± 10.9 26.5 ± 1.2 
E/e’ 15.2 ± 6.7 24.5 ± 14.3 
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Table 3. Echocardiographic views and parameters that should be specifically recorded to characterize cardiac function when 
working with distinct animal models. A, late diastolic transmitral flow velocities; BW, body weight; CO, cardiac output; E, early 
diastolic transmitral flow velocities; e’, peak early-diastolic annular velocity; EF, ejection fraction; FS, fractional shortening; HR, 
heart rate; IVRT, isovolumic relaxation time; IVSd, interventricular septum thickness in diastole; IVSs, interventricular septum 
thickness in systole; LAA, left atrial area; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVIDd, left ventricle internal diameter in diastole; LVIDs, left ventricle internal diameter in systole; LV mass, left ventricle mass; 
LVPWd, left ventricular posterior wall thickness in diastole; LVPWs, left ventricular posterior wall thickness in systole; MPI, 
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Animal 

















Two-dimensional B-mode and 
M-mode, parasternal long 
and/or short-axis view 
Record diastolic and systolic LV wall thickness and chamber dimensions to calculate: 
- LVESV = (7 / (2.4 + LVIDs)) x LVIDs3 
- LVEDV = (7 / (2.4 + LVIDd)) x LVIDd3 
- FS (%) = (LVIDd - LVIDs) / LVIDd x 100 
- EF (%) = (LVEDV - LVESV) / LVEDV x 100 
- LV mass (mg) = 1.04 [(LVIDd + LVAWd + LVPWd)3 - LVIDd3] x 0.8 + 0.6 
- Stroke volume, SV (µl) = (LVEDV – LVESV) 
- Cardiac output (µl/min): CO = SV x HR 
- Relative wall thickness: RWT = (LVPWd + LVIVSd) / (LVIDd) 
Two-dimensional PW doppler 
echocardiography, supra-
sternal or neck position 
Record the pressure gradient across the constricted portion of ascending aorta and/or the right/left carotid 
velocity flow ratio (expected to be 5-10) 
Pulsed wave Doppler mode 
and Tissue Doppler mode, 
apical four- or five-chamber 
views 
Record diastolic parameters: 
- Early and late mitral filling velocities (E and A wave) 
- E wave deceleration time (DT) 
- Early diastolic mitral annular tissue velocity (e’) 
- Isovolumic relaxation time (IVRT) 
- Ejection time (ET) 
Two-dimensional B-mode, 
apical four-chamber view 














Two-dimensional B-mode and 
M-mode, parasternal long-
axis and short-axis views 
 
 
Record diastolic and systolic LV wall thickness and chamber size and use the Simpson’s method to calculate: 
- LV area at the level of mitral valve (A1, as in Figure 4, panels a) in systole and diastole 
- LV area at the level of the papillary muscles (A2, as in Figure 4, panels b) in systole and diastole 
- LV area at the level of the apex (A3, as in Figure 4, panels c) in systole and diastole 
- The maximum length of the ventricle in parasternal long-axis, in systole (LVESL) and diastole (LVEDL) 
- LVEDV = (A1+A2) x (LVEDL/3) + (A3/2) x (LVEDL/3) + (π/6) x (LVEDL/3)3 
- LVESV = (A1+A2) x (LVESL/3) + (A3/2) x (LVESL/3) + (π/6) x (LVESL/3)3 
- EF (%) = (LVEDV-LVESV) / LVEDV x 100 
- Aortic annulus diameter 
Pulsed wave Doppler and 
Tissue Doppler mode, apical 
four- or five-chamber view at 
the medial mitral annulus 
 
 
Record systolic parameters: 
- Isovolumetric contraction time (IVCT)  
- Ejection time (ET)  
- Myocardial performance index (MPI/Tei) = (IVCT + IVRT) / ET 
- LV systolic myocardial velocity (s’) at the level of the septal mitral annulus 
Record and calculate aortic parameters: 
- Aortic annulus velocity (VTI) 





















Two-dimensional B-mode and 
M-mode, parasternal long 








Record diastolic and systolic LV wall thickness and chamber dimensions to calculate: 
- LVESV = (7 / (2.4 + LVIDs)) x LVIDs3 
- LVEDV = (7 / (2.4 + LVIDd)) x LVIDd3 
- FS (%) = (LVIDd - LVIDs) / LVIDd x 100 
- EF (%) = (LVEDV - LVESV) / LVEDV x 100 
- LV mass (mg) = 1.04 [(LVIDd + LVAWd + LVPWd)3 - LVIDd3] x 0.8 + 0.6 
- Stroke volume, SV (µl) = (LVEDV – LVESV) 
- Cardiac output (µl/min): CO = SV x HR 
- Relative wall thickness: RWT = (LVPWd + LVIVSd) / (LVIDd) 
 
Pulsed wave Doppler or Tissue 
Doppler mode, apical four-
chamber view at the medial 
mitral annulus 
Record diastolic parameters: 
- Early and late mitral filling velocities (E and A wave) 
- E wave deceleration time  
- Isovolumic relaxation time (IVRT) 
- Peak mitral annular velocity (E´) during early filling at septal or lateral corner of the mitral annulus. 
Record systolic parameters: 
- Ejection time (ET) 
- LV index of myocardial performance = (IVCT+IVRT)/ET  











apical four-chamber view 
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